On December 3, 2021, NeoCura Bio-Medical Technology Co., Ltd. (“NeoCura”), a leading RNA-based drug research and development company in China, and Integrated Nanotherapeutics Inc. (“INT”), a cutting-edge biotechnology company in Canada, jointly announce that both parties have entered into a strategic collaboration agreement to explore global next-generation LNP system for the delivery of mRNA drugs.

According to the agreement, the global next-generation LNP (Lipid NanoParticle) delivery technology developed by INT will be combined with the innovative mRNA drugs of NeoCura to optimize the delivery effect of mRNA drugs so as to explore multi-target and multi-indication therapies, giving full play to the application potential of mRNA drugs in various diseases. Both parties will jointly own the intellectual property created through this collaboration achievement, and NeoCura is expected to obtain the global exclusive rights to develop certain gene and RNA therapy programs under the terms agreed by both parties.

The delivery system is one of the key technologies that enable mRNA drugs to reach its full therapeutic potentials. INT's proprietary scaffold-lipid platform is the world's FIRST technology that is compatible with all drug modalities and the ONLY technology that enables the co-loading of different drug modalities in the same nanoparticle. Dr. Pieter Cullis, one of the INT founding team, is well known as the "Father of Lipid Nanotechnology". He started his journey in studying the delivery of mRNA drug via lipid nanoparticles more than 40 years ago and was awarded the Prince Mahidol Award for his pioneering contribution to the field of lipid nanoparticles. This strategic collaboration adds to the ever-growing armamentarium of NeoCura in delivering mRNA drugs more efficiently, effectively and specifically.

Dr. Yi WANG, Founder and CEO of NeoCura, said: "It’s such an honor for us to become strategic partner of INT. I believe the two parties have complementary know-how, and we can work together to enhance the effectiveness of mRNA drug research and development. The INT team has more than 80 years of experience in the research of LNP delivery, and their proprietary novel LNP delivery system enjoys significant advantages in mRNA drug delivery. This international collaboration will surely give strong boost to NeoCura’s mRNA drug development and commercialization. NeoCura is becoming an open platform to embrace broad innovations for advancing RNA medicine.”

Dr. Chris TAM, CEO and Co-Founder of INT stated: “We are very impressed with NeoCura’s innovative RNA drug platform and manufacturing capabilities, and excited to collaborate with NeoCura team to develop novel lipid nanoparticle systems based on our lipid-scaffold technology. INT has established a powerful research blueprint that uses our technology to leverage existing biological processes to accelerate innovation. With the complementary R&D expertise in RNA and lipid nanoparticles, we envision a robust and productive collaboration that will advance RNA medicines and generate clinical impact. We look forward to deepening the partnership between our companies in the future.”

About NeoCura

NeoCura, a R&D based China biotech featuring AI-enabled RNA precision medicine and focusing on oncology. Founded in 2017, NeoCura is committed to building a global leading RNA innovative drug platform. NeoCura brings together the world's top scientists, senior industry experts and first-class academic consultants. The core R&D team includes dozens of doctoral/postdoctoral fellows from prestigious schools such as Harvard, Cambridge, Cornell, Tsinghua University, Peking University, and Chinese Academy of Sciences. NeoCura has built multi-omics data collection platform and corresponding omics database, used proprietary AI and bioinformatics technologies for therapeutic target deep mining and fully automated drug design. To date, over 10 pipelines are under development covering tumor neoantigen vaccines, tumor microenvironment modulations etc. NeoCura also built a leading RNA drug manufacturing center in China to fulfill R&D and clinical needs.

With its multiple leading technologies, outstanding innovation capability and robust oncology pipelines, NeoCura is recognized as one of the Most Promising Enterprise in China and Top 10 China AI/Algorithm Innovative Pharmaceutical Enterprise in 2021.

About INT

Established in 2014, Integrated  Nanotherapeutics Inc. (INT) is a private biotechnology company   based in Vancouver, Canada. INT is a global leader in engineering and developing biocompatible lipid nanoparticle systems that allow various drugs to reach their full therapeutic potential as safe and effective nanomedicines. The company’s proprietary scaffold-lipid platform allows any drug modality (including small molecules, nucleic acids and peptides) to be efficiently entrapped in lipid nanoparticles and delivered to disease tissues and cells. This platform technology is the first of its kind that is compatible with all drug modalities and is the only available technology that can co-load different drug modalities in the same nanoparticle, enabling combination therapies in a single formulation.

INT’s founders and management have extensive prior research contributions that have led to 5 approved lipid-based nanomedicines currently on the market (Abelcet^®, Myocet^®, Marqibo^®, Onpattro^®and Comirnaty^®). Building upon on its deep expertise in lipid nanoparticle design and manufacture, INT has an internal pipeline focused on autoimmune disorders and is working with its partners to develop novel nanomedicines for various human diseases.

Contact:

E-mail: bd@neocura.net

Tel:+86 10 8076 6127

Web: http://www.neocura.com.cn